Special: ECTRIMS 2024 - Personalized MS treatments, genetic risk factors and the benefits of early, effective therapies for women and children

Special: ECTRIMS 2024 - Personalized MS treatments, genetic risk factors and the benefits of early, effective therapies for women and children

Personalized treatments, genetic risk factors, gender differences and the advantages of early, highly effective therapies.

You can read the full article here: https://ms-perspektive.com/ectrims-2024-ww1

This year, ECTRIMS 2024 in Copenhagen, Denmark, will once again bring together leading experts in multiple sclerosis (MS) from around the world. The prestigious conference is the premier event for researchers, physicians and healthcare professionals all working towards a common goal: improving quality of life through groundbreaking research and advances in the treatment of MS and related diseases. The event, which is expected to attract around 9,000 attendees, promises a rich program of inspiring keynote addresses, exciting oral and poster presentations, and carefully curated scientific and educational sessions. In addition, there will be numerous opportunities for networking and connecting with the international MS community. I have brought you some exciting papers to start my coverage of this year's event.

From biomarkers that help predict disease progression to new insights into genetic risk factors and gender differences in treatment, these results underscore the growing importance of personalized care in the management of MS. Key findings include the benefits of early, high-potency treatments for children, the association of inherited genetic variants with MS risk, and the therapeutic inertia in the management of women with MS. These studies pave the way for more targeted and effective treatment strategies that could transform outcomes for people with MS worldwide.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(193)

#191: BTK inhibitors in MS: where do we stand after ECTRIMS/ACTRIMS 2026?

#191: BTK inhibitors in MS: where do we stand after ECTRIMS/ACTRIMS 2026?

BTK inhibitors have produced different results in multiple sclerosis trials. In episode no. 191, I explore what we learned at ECTRIMS/ACTRIMS 2026 about individual medicines, their potential benefits ...

11 Marras 19min

#190: Living with multiple sclerosis. Gabriela's story and the "(un)seen faces of MS" Art Project

#190: Living with multiple sclerosis. Gabriela's story and the "(un)seen faces of MS" Art Project

https://ms-perspektive.de/en/190-unseen-faces-of-ms/Living with multiple sclerosis often means experiencing symptoms that others cannot see. Austrian artist Gabriela Romagna shares her journey to an M...

4 Marras 32min

#189: New imaging in MS: understanding progression and finding better treatments | ECTRIMS 2026

#189: New imaging in MS: understanding progression and finding better treatments | ECTRIMS 2026

How could new imaging in MS help us understand progression and develop better treatments? In this episode, I explore key insights from Daniel Reich's MSToronto2026 lecture and related research. Learn ...

28 Loka 15min

#188: Jan Van Amstel on EMSP's Four-Year Presidency and the Future of MS Advocacy in Europe

#188: Jan Van Amstel on EMSP's Four-Year Presidency and the Future of MS Advocacy in Europe

"Get rid of MS as soon as possible and make ourselves superfluous." — Jan van Amstel What can a stronger European voice achieve for people living with MS? In episode #188, EMSP President Jan van Amste...

21 Loka 31min

#187: Aging in multiple sclerosis: relapses, progression and treatment choices with Dr. Yi Chao Foong

#187: Aging in multiple sclerosis: relapses, progression and treatment choices with Dr. Yi Chao Foong

Aging in multiple sclerosis brings new questions about relapses, gradual progression and treatment choices. In episode 187, Dr. Yi Chao Foong, an MS neurologist and researcher in Tasmania, explains wh...

14 Loka 29min

#186: Protecting nerve cells in multiple sclerosis: A new path toward neuroprotection with Prof. Manuel Friese

#186: Protecting nerve cells in multiple sclerosis: A new path toward neuroprotection with Prof. Manuel Friese

Why can multiple sclerosis progress even when relapses are well controlled? In episode 186, I speak with Prof. Manuel Friese about the next challenge in MS research: protecting nerve cells from damage...

7 Loka 43min

#185: Living with MS in Mexico – who gets diagnosed, who gets treated, and who gets left behind?

#185: Living with MS in Mexico – who gets diagnosed, who gets treated, and who gets left behind?

An MS diagnosis can depend on where you live, whether you can reach a neurologist and how quickly you can get an MRI. In this episode, Nele speaks with neurologist and neuroimmunologist Dr. Enrique Go...

30 Syys 36min

#184: MS treatment across the disease course – treat early, think long-term, don't give up too soon with Prof. Klaus Schmierer

#184: MS treatment across the disease course – treat early, think long-term, don't give up too soon with Prof. Klaus Schmierer

Read the full blog post and interview here: https://ms-perspektive.de/en/184-klaus-schmierer/ How early should MS treatment start, how strongly should we treat, and is there ever a point when it becom...

23 Syys 41min

Suosittua kategoriassa Koulutus

rss-murhan-anatomia
aamukahvilla
psykopodiaa-podcast
rss-hereilla
voi-hyvin-meditaatiot-2
rss-suomen-aa-podcast
rss-liian-kuuma-peruna
rss-arkea-ja-aurinkoa-podcast-espanjasta
adhd-podi
aloita-meditaatio
kesken
rss-vapaudu-voimaasi
rahapuhetta
rss-luonnollinen-synnytys-podcast
rss-monarch-talk-with-alexandra-alexis
rss-narsisti
ihminen-tavattavissa-tommy-hellsten-instituutti
psykologia
rss-uskonto-on-tylsaa
rss-duodecim-lehti